Tejas Patil, Derek E Smith, Paul A Bunn, Dara L Aisner, Anh T Le, Mark Hancock, William T Purcell, Daniel W Bowles, D Ross Camidge, Robert C Doebele. J Thorac Oncol 2018
Times Cited: 66
Times Cited: 66
Times Cited
Times Co-cited
Similarity
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz,[...]. JCO Precis Oncol 2017
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz,[...]. JCO Precis Oncol 2017
54
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi,[...]. J Clin Oncol 2017
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi,[...]. J Clin Oncol 2017
50
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
46
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
43
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
39
ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
37
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
37
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
37
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
33
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
31
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
31
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
30
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
28
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
27
RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
25
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
25
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
25
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
25
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
24
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
22
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
21
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
21
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi,[...]. J Thorac Oncol 2018
Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi,[...]. J Thorac Oncol 2018
27
Recent Advances in Targeting ROS1 in Lung Cancer.
Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
19
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
19
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
19
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
S Gadgeel, S Peters, T Mok, A T Shaw, D W Kim, S I Ou, M Pérol, A Wrona, S Novello, R Rosell,[...]. Ann Oncol 2018
S Gadgeel, S Peters, T Mok, A T Shaw, D W Kim, S I Ou, M Pérol, A Wrona, S Novello, R Rosell,[...]. Ann Oncol 2018
19
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
19
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon,[...]. Clin Cancer Res 2016
Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remon,[...]. Clin Cancer Res 2016
19
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
29
An unexpected error occurred.
Please provide the following information to technical support:
Error Event: onRequest
Error details:
struct | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cause |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Detail | An exception occurred while invoking an event handler method from Application.cfc. The method name is: onRequest. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Message | Event handler exception. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RootCause |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
StackTrace | coldfusion.runtime.EventHandlerException: Event handler exception. at coldfusion.runtime.AppEventInvoker.onRequest(AppEventInvoker.java:319) at coldfusion.filter.ApplicationFilter.invoke(ApplicationFilter.java:551) at coldfusion.filter.RequestMonitorFilter.invoke(RequestMonitorFilter.java:43) at coldfusion.filter.MonitoringFilter.invoke(MonitoringFilter.java:40) at coldfusion.filter.PathFilter.invoke(PathFilter.java:162) at coldfusion.filter.IpFilter.invoke(IpFilter.java:45) at coldfusion.filter.ExceptionFilter.invoke(ExceptionFilter.java:96) at coldfusion.filter.ClientScopePersistenceFilter.invoke(ClientScopePersistenceFilter.java:28) at coldfusion.filter.BrowserFilter.invoke(BrowserFilter.java:38) at coldfusion.filter.NoCacheFilter.invoke(NoCacheFilter.java:60) at coldfusion.filter.GlobalsFilter.invoke(GlobalsFilter.java:38) at coldfusion.filter.DatasourceFilter.invoke(DatasourceFilter.java:22) at coldfusion.filter.CachingFilter.invoke(CachingFilter.java:62) at coldfusion.CfmServlet.service(CfmServlet.java:226) at coldfusion.bootstrap.BootstrapServlet.service(BootstrapServlet.java:311) at org.apache.catalina.core.ApplicationFilterChain.internalDoFilter(ApplicationFilterChain.java:228) at org.apache.catalina.core.ApplicationFilterChain.doFilter(ApplicationFilterChain.java:163) at coldfusion.monitor.event.MonitoringServletFilter.doFilter(MonitoringServletFilter.java:46) at coldfusion.bootstrap.BootstrapFilter.doFilter(BootstrapFilter.java:47) at org.apache.catalina.core.ApplicationFilterChain.internalDoFilter(ApplicationFilterChain.java:190) at org.apache.catalina.core.ApplicationFilterChain.doFilter(ApplicationFilterChain.java:163) at org.apache.tomcat.websocket.server.WsFilter.doFilter(WsFilter.java:53) at org.apache.catalina.core.ApplicationFilterChain.internalDoFilter(ApplicationFilterChain.java:190) at org.apache.catalina.core.ApplicationFilterChain.doFilter(ApplicationFilterChain.java:163) at org.apache.catalina.core.StandardWrapperValve.invoke(StandardWrapperValve.java:202) at org.apache.catalina.core.StandardContextValve.invoke(StandardContextValve.java:97) at org.apache.catalina.authenticator.AuthenticatorBase.invoke(AuthenticatorBase.java:542) at org.apache.catalina.core.StandardHostValve.invoke(StandardHostValve.java:143) at org.apache.catalina.valves.ErrorReportValve.invoke(ErrorReportValve.java:92) at org.apache.catalina.core.StandardEngineValve.invoke(StandardEngineValve.java:78) at org.apache.catalina.connector.CoyoteAdapter.service(CoyoteAdapter.java:373) at org.apache.coyote.ajp.AjpProcessor.service(AjpProcessor.java:462) at org.apache.coyote.AbstractProcessorLight.process(AbstractProcessorLight.java:65) at org.apache.coyote.AbstractProtocol$ConnectionHandler.process(AbstractProtocol.java:893) at org.apache.tomcat.util.net.NioEndpoint$SocketProcessor.doRun(NioEndpoint.java:1723) at org.apache.tomcat.util.net.SocketProcessorBase.run(SocketProcessorBase.java:49) at java.base/java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1128) at java.base/java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:628) at org.apache.tomcat.util.threads.TaskThread$WrappingRunnable.run(TaskThread.java:61) at java.base/java.lang.Thread.run(Thread.java:834) Caused by: coldfusion.runtime.UDFMethod$InvalidArgumentTypeException: The COCITEDARTICLECITATION_COUNT argument passed to the calculArticleSimilarity function is not of type numeric. at coldfusion.runtime.UDFMethod._validateArgWithValidator(UDFMethod.java:1434) at coldfusion.runtime.UDFMethod._validateRequiredArg(UDFMethod.java:1400) at cfpubmed2ecfc1897273376$funcCALCULARTICLESIMILARITY.runFunction(C:\home\cocites.com\wwwroot\cfc\pubmed.cfc:215) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:554) at coldfusion.runtime.UDFMethod$ReturnTypeFilter.invoke(UDFMethod.java:485) at coldfusion.runtime.UDFMethod$ArgumentCollectionFilter.invoke(UDFMethod.java:448) at coldfusion.filter.FunctionAccessFilter.invoke(FunctionAccessFilter.java:95) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:399) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:372) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:288) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:830) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:613) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:438) at coldfusion.runtime.CfJspPage._invoke(CfJspPage.java:3627) at coldfusion.runtime.CfJspPage._invoke(CfJspPage.java:3604) at cfcoCitedArticles2ecfm1072712._factor11(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:483) at cfcoCitedArticles2ecfm1072712._factor14(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:401) at cfcoCitedArticles2ecfm1072712._factor15(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:321) at cfcoCitedArticles2ecfm1072712._factor17(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:298) at cfcoCitedArticles2ecfm1072712.runPage(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:1) at coldfusion.runtime.CfJspPage.invoke(CfJspPage.java:262) at coldfusion.tagext.lang.IncludeTag.handlePageInvoke(IncludeTag.java:735) at coldfusion.tagext.lang.IncludeTag.doStartTag(IncludeTag.java:565) at coldfusion.runtime.CfJspPage._emptyTcfTag(CfJspPage.java:4329) at cfApplication2ecfc1402755519$funcONREQUEST.runFunction(C:\home\cocites.com\wwwroot\Application.cfc:182) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:554) at coldfusion.runtime.UDFMethod$ReturnTypeFilter.invoke(UDFMethod.java:485) at coldfusion.runtime.UDFMethod$ArgumentCollectionFilter.invoke(UDFMethod.java:448) at coldfusion.filter.FunctionAccessFilter.invoke(FunctionAccessFilter.java:95) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:399) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:372) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:288) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:830) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:613) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:438) at coldfusion.runtime.AppEventInvoker.invoke(AppEventInvoker.java:115) at coldfusion.runtime.AppEventInvoker.onRequest(AppEventInvoker.java:308) ... 39 more | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Suppressed |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TagContext |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type | Application | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
name | onRequest |